Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.

Luca Richeldi,Martin Kolb,Stéphane Jouneau,Wim Wuyts,Birgit Schinzel,Susanne Stowasser,Manuel Quaresma,Ganesh Raghu

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.

2020

Luca Richeldi
Martin Kolb
Stéphane Jouneau
Wim Wuyts
Birgit Schinzel
Susanne Stowasser
Manuel Quaresma
Ganesh Raghu

BACKGROUND: The two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC >/=50% predicted and DLco 30-79% predicted. The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients with IPF and DLco

Keywords:

Idiopathic pulmonary fibrosis
Intensive care medicine
Medicine
Nintedanib
Placebo
Internal medicine
DLCO
FEV1/FVC ratio
Adverse effect
Exacerbation
Tolerability

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations